IdeaWazaWiki - User contributions [en]

Medherant

2025-10-24T11:58:49Z

137.205.213.65: added wiki link to david haddleton

{{POV|date=August 2023}}
{{Short description|British pharmaceutical company}}
{{Use dmy dates|date=October 2017}}
{{Use British English|date=October 2017}}
{{self-published|date=October 2016}}

{{Infobox company
| name = Medherant Ltd
| logo = File:Medherant Ltd logo.png
| type = [[Private Limited Company]]
| industry = [[Pharmaceuticals]]
| founded = 2015
| founder = Professor David Haddleton
| hq_location_city = Coventry
| hq_location_country = United Kingdom
| website = {{Official website |www.medherant.co.uk}}
}}

'''[https://www.medherant.co.uk/ Medherant Ltd]''' is a British [[pharmaceutical company]], based in [[Coventry]]. The company is developing [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]].

==History==
Medherant Ltd was founded as a [[university spin-off]] by [[David Haddleton|Professor David Haddleton]] and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.
Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and has received over £15M investment by the end of 2025.

==Research==
Using its research in [[bioadhesive|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal |last=Efstathiou |first=Spyridon |last2=Nurumbetov |first2=Gabit |last3=Ross |first3=Andrew |last4=Li |first4=Yongguang |last5=Haddleton |first5=David M. |date=2024-04-22 |title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) |url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f |journal=Materials Advances |language=en |volume=5 |issue=8 |pages=3396–3410 |doi=10.1039/D3MA01104F |issn=2633-5409}}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web |url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ |title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin |publisher=University of Warwick |accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web |url=http://www.medherant.co.uk/about-us |title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines |publisher=Medherant Ltd |accessdate=16 October 2016}}</ref>

Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news |date=2023-04-03 |title=Menopause testosterone patch to begin trials |url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 |access-date=2025-10-24 |work=BBC News |language=en-GB}}</ref> which has shown excellent results to date.<ref>{{Cite web |title=Medherant announces positive Phase 1 clinical trial results |url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results |access-date=2025-10-24 |website=warwick.ac.uk}}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].

==References==
{{reflist}}

==External links==
* [http://www.haddleton.org Haddleton Group]

[[Category:Companies based in Coventry]]
[[Category:Pharmaceutical companies of the United Kingdom]]

Medherant

2025-10-24T11:56:55Z

137.205.213.65: added bbc reference

{{POV|date=August 2023}}
{{Short description|British pharmaceutical company}}
{{Use dmy dates|date=October 2017}}
{{Use British English|date=October 2017}}
{{self-published|date=October 2016}}

{{Infobox company
| name = Medherant Ltd
| logo = File:Medherant Ltd logo.png
| type = [[Private Limited Company]]
| industry = [[Pharmaceuticals]]
| founded = 2015
| founder = Professor David Haddleton
| hq_location_city = Coventry
| hq_location_country = United Kingdom
| website = {{Official website |www.medherant.co.uk}}
}}

'''[https://www.medherant.co.uk/ Medherant Ltd]''' is a British [[pharmaceutical company]], based in [[Coventry]]. The company is developing [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]].

==History==
Medherant Ltd was founded as a [[university spin-off]] by Professor David Haddleton and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.
Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and has received over £15M investment by the end of 2025.

==Research==
Using its research in [[bioadhesive|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal |last=Efstathiou |first=Spyridon |last2=Nurumbetov |first2=Gabit |last3=Ross |first3=Andrew |last4=Li |first4=Yongguang |last5=Haddleton |first5=David M. |date=2024-04-22 |title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) |url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f |journal=Materials Advances |language=en |volume=5 |issue=8 |pages=3396–3410 |doi=10.1039/D3MA01104F |issn=2633-5409}}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web |url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ |title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin |publisher=University of Warwick |accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web |url=http://www.medherant.co.uk/about-us |title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines |publisher=Medherant Ltd |accessdate=16 October 2016}}</ref>

Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news |date=2023-04-03 |title=Menopause testosterone patch to begin trials |url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 |access-date=2025-10-24 |work=BBC News |language=en-GB}}</ref> which has shown excellent results to date.<ref>{{Cite web |title=Medherant announces positive Phase 1 clinical trial results |url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results |access-date=2025-10-24 |website=warwick.ac.uk}}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].

==References==
{{reflist}}

==External links==
* [http://www.haddleton.org Haddleton Group]

[[Category:Companies based in Coventry]]
[[Category:Pharmaceutical companies of the United Kingdom]]

Medherant

2025-10-24T11:55:37Z

137.205.213.65: updated material and added recent citations

{{POV|date=August 2023}}
{{Short description|British pharmaceutical company}}
{{Use dmy dates|date=October 2017}}
{{Use British English|date=October 2017}}
{{self-published|date=October 2016}}

{{Infobox company
| name = Medherant Ltd
| logo = File:Medherant Ltd logo.png
| type = [[Private Limited Company]]
| industry = [[Pharmaceuticals]]
| founded = 2015
| founder = Professor David Haddleton
| hq_location_city = Coventry
| hq_location_country = United Kingdom
| website = {{Official website |www.medherant.co.uk}}
}}

'''[https://www.medherant.co.uk/ Medherant Ltd]''' is a British [[pharmaceutical company]], based in [[Coventry]]. The company is developing [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]].

==History==
Medherant Ltd was founded as a [[university spin-off]] by Professor David Haddleton and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.
Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and has received over £15M investment by the end of 2025.

==Research==
Using its research in [[bioadhesive|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal |last=Efstathiou |first=Spyridon |last2=Nurumbetov |first2=Gabit |last3=Ross |first3=Andrew |last4=Li |first4=Yongguang |last5=Haddleton |first5=David M. |date=2024-04-22 |title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) |url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f |journal=Materials Advances |language=en |volume=5 |issue=8 |pages=3396–3410 |doi=10.1039/D3MA01104F |issn=2633-5409}}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web |url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ |title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin |publisher=University of Warwick |accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web |url=http://www.medherant.co.uk/about-us |title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines |publisher=Medherant Ltd |accessdate=16 October 2016}}</ref>

Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women which has shown excellent results to date.<ref>{{Cite web |title=Medherant announces positive Phase 1 clinical trial results |url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results |access-date=2025-10-24 |website=warwick.ac.uk}}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].

==References==
{{reflist}}

==External links==
* [http://www.haddleton.org Haddleton Group]

[[Category:Companies based in Coventry]]
[[Category:Pharmaceutical companies of the United Kingdom]]